Navigation Links
AMP joins the Federation of American Societies for Experimental Biology
Date:6/18/2013

Bethesda, MD, June 18, 2013: The Association for Molecular Pathology is proud to announce it will join the Federation of American Societies for Experimental Biology (FASEB) on July 1, 2013. The FASEB Board approved AMP's application for membership on June 3, 2013.

The 26 constituent societies of FASEB represent more than 100,000 individuals and share a common vision for the advancement of research and education in biological and biomedical sciences. "Basic biomedical and translational research is more important now than ever," said Jennifer L. Hunt, MD, MEd, AMP President, "being a member of FASEB will enable AMP's voice to be even stronger."

AMP's 2,000+ members represent a unique and vitally important cross-section of specialties and subspecialties in the molecular pathology and diagnostic environment. "We are proud to have them as members," said FASEB President, Judith Bond, PhD, "We welcome the addition of their perspectives to our advocacy efforts and look forward to working closely with them on critically important research issues."


'/>"/>

Contact: Catherine Davidge
cdavidge@amp.org
301-634-7400
Association for Molecular Pathology
Source:Eurekalert

Page: 1

Related biology news :

1. Steve Fisher joins American Health IT LLC as VP of Operations
2. Brazil joins international marine research effort
3. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
4. Brazil joins global initiative for biodiversity data access
5. Book shows evolution that joins human and environmental sciences
6. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
7. Warren Lammert Joins IntelliMedix Board of Advisors
8. Denmark joins the Nordic EMBL Partnership for Molecular Medicine
9. Einstein joins the New York Genome Center as 12th institutional founding member
10. CARE Pharmacies Joins National Association of Specialty Pharmacy (NASP) as a Founding Corporate Member
11. Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 ... genomic services and solutions with cutting edge next-generation sequencing ... completed a USD $75 Million [515 Million RMB] B ... International Capital Management ( Shenzhen ) Co., ... ("SDIC Innovation") and Shanghai Sigma Square Investment Center LP ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule cocrystal ... the latest FDA guidance on pharmaceutical cocrystals as drug substance . The ... , The event follows the successful November 15th event that took place in ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... the development of a new orally administered treatment for Alzheimer’s disease (AD), today ... of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s ...
Breaking Biology Technology: